Back to Search
Start Over
Mepolizumab in eosinophilic disorders
- Publication Year :
- 2011
-
Abstract
- Mepolizumab (Bosatria(®), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.
- Subjects :
- Immunology
Drug Evaluation, Preclinical
Churg-Strauss Syndrome
Antibodies, Monoclonal, Humanized
Article
Eosinophilic disorder
Eosinophilia
Hypereosinophilic Syndrome
Immunology and Allergy
Medicine
Animals
Humans
Interleukin 5
Asthma
Clinical Trials as Topic
business.industry
Antibodies, Monoclonal
medicine.disease
Anti il 5
Eosinophils
Monoclonal
Interleukin-5
business
Mepolizumab
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....9cb039576d12ec4e940b71090a24f657